## **Core Concept**
Sirolimus, also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation. It works by inhibiting the mammalian target of rapamycin (mTOR), which plays a critical role in cell proliferation. The route of administration for sirolimus is crucial for its bioavailability and efficacy.

## **Why the Correct Answer is Right**
The correct answer, oral route, is right because sirolimus is administered orally. It is a lipophilic compound, and its oral bioavailability is variable but can be optimized with a consistent dosing regimen. The oral route allows for the drug to be absorbed into the bloodstream, where it can then bind to FK-binding protein-12 (FKBP-12) and inhibit mTOR.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Intravenous route is incorrect because while some immunosuppressants are administered intravenously, sirolimus is not typically given this way due to its pharmacokinetic profile and potential for adverse effects.
- **Option B:** Topical route is incorrect because sirolimus is a systemic immunosuppressant and not used topically for its immunosuppressive effects.
- **Option C:** Inhalation route is incorrect because sirolimus is not administered via inhalation; this route is typically reserved for drugs that act directly on the lungs.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that sirolimus levels can be monitored using trough blood levels, similar to other immunosuppressants, to ensure therapeutic efficacy while minimizing toxicity. Sirolimus has a different side effect profile compared to calcineurin inhibitors, with less nephrotoxicity but potentially more hyperlipidemia and thrombocytopenia.

## **Correct Answer:** . Oral.